BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 8967990)

  • 1. Identification and pharmacological characterization of [125I]L-750,667, a novel radioligand for the dopamine D4 receptor.
    Patel S; Patel S; Marwood R; Emms F; Marston D; Leeson PD; Curtis NR; Kulagowski JJ; Freedman SB
    Mol Pharmacol; 1996 Dec; 50(6):1658-64. PubMed ID: 8967990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The agonist activities of the putative antipsychotic agents, L-745,870 and U-101958 in HEK293 cells expressing the human dopamine D4.4 receptor.
    Gazi L; Bobirnac I; Danzeisen M; Schüpbach E; Bruinvels AT; Geisse S; Sommer B; Hoyer D; Tricklebank M; Schoeffter P
    Br J Pharmacol; 1998 Jul; 124(5):889-96. PubMed ID: 9692773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biological profile of L-745,870, a selective antagonist with high affinity for the dopamine D4 receptor.
    Patel S; Freedman S; Chapman KL; Emms F; Fletcher AE; Knowles M; Marwood R; Mcallister G; Myers J; Curtis N; Kulagowski JJ; Leeson PD; Ridgill M; Graham M; Matheson S; Rathbone D; Watt AP; Bristow LJ; Rupniak NM; Baskin E; Lynch JJ; Ragan CI
    J Pharmacol Exp Ther; 1997 Nov; 283(2):636-47. PubMed ID: 9353380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [35S]Guanosine-5'-O-(3-thio)triphosphate binding as a measure of efficacy at human recombinant dopamine D4.4 receptors: actions of antiparkinsonian and antipsychotic agents.
    Newman-Tancredi A; Audinot V; Chaput C; Verrièle L; Millan MJ
    J Pharmacol Exp Ther; 1997 Jul; 282(1):181-91. PubMed ID: 9223553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. S 18126 ([2-[4-(2,3-dihydrobenzo[1,4]dioxin-6-yl)piperazin-1-yl methyl]indan-2-yl]), a potent, selective and competitive antagonist at dopamine D4 receptors: an in vitro and in vivo comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2, 3b]pyridine) and raclopride.
    Millan MJ; Newman-Tancredi A; Brocco M; Gobert A; Lejeune F; Audinot V; Rivet JM; Schreiber R; Dekeyne A; Spedding M; Nicolas JP; Peglion JL
    J Pharmacol Exp Ther; 1998 Oct; 287(1):167-86. PubMed ID: 9765336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-[4-(3,4-Dimethylphenyl)piperazin-1-ylmethyl]-1H benzoimidazole (A-381393), a selective dopamine D4 receptor antagonist.
    Nakane M; Cowart MD; Hsieh GC; Miller L; Uchic ME; Chang R; Terranova MA; Donnelly-Roberts DL; Namovic MT; Miller TR; Wetter JM; Marsh K; Stewart AO; Brioni JD; Moreland RB
    Neuropharmacology; 2005 Jul; 49(1):112-21. PubMed ID: 15992586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. I. NGD 94-1: identification of a novel, high-affinity antagonist at the human dopamine D4 receptor.
    Tallman JF; Primus RJ; Brodbeck R; Cornfield L; Meade R; Woodruff K; Ross P; Thurkauf A; Gallager DW
    J Pharmacol Exp Ther; 1997 Aug; 282(2):1011-9. PubMed ID: 9262370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel heterocyclic trans olefin analogues of N-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor.
    Grundt P; Carlson EE; Cao J; Bennett CJ; McElveen E; Taylor M; Luedtke RR; Newman AH
    J Med Chem; 2005 Feb; 48(3):839-48. PubMed ID: 15689168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional coupling of human D2, D3, and D4 dopamine receptors in HEK293 cells.
    McAllister G; Knowles MR; Ward-Booth SM; Sinclair HA; Patel S; Marwood R; Emms F; Patel S; Smith A; Seabrook GR
    J Recept Signal Transduct Res; 1995; 15(1-4):267-81. PubMed ID: 8903944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [3H] A-369508 ([2-[4-(2-cyanophenyl)-1-piperazinyl]-N-(3-methylphenyl) acetamide): an agonist radioligand selective for the dopamine D4 receptor.
    Moreland RB; Terranova MA; Chang R; Uchic ME; Matulenko MA; Surber BW; Stewart AO; Brioni JD
    Eur J Pharmacol; 2004 Aug; 497(2):147-54. PubMed ID: 15306199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents.
    Sautel F; Griffon N; Sokoloff P; Schwartz JC; Launay C; Simon P; Costentin J; Schoenfelder A; Garrido F; Mann A
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1239-46. PubMed ID: 8531087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.
    Audinot V; Newman-Tancredi A; Gobert A; Rivet JM; Brocco M; Lejeune F; Gluck L; Desposte I; Bervoets K; Dekeyne A; Millan MJ
    J Pharmacol Exp Ther; 1998 Oct; 287(1):187-97. PubMed ID: 9765337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy.
    Millan MJ; Peglion JL; Vian J; Rivet JM; Brocco M; Gobert A; Newman-Tancredi A; Dacquet C; Bervoets K; Girardon S
    J Pharmacol Exp Ther; 1995 Nov; 275(2):885-98. PubMed ID: 7473180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression and pharmacological characterization of the human D3 dopamine receptor.
    Freedman SB; Patel S; Marwood R; Emms F; Seabrook GR; Knowles MR; McAllister G
    J Pharmacol Exp Ther; 1994 Jan; 268(1):417-26. PubMed ID: 8301582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacological characterization of U-101387, a dopamine D4 receptor selective antagonist.
    Merchant KM; Gill GS; Harris DW; Huff RM; Eaton MJ; Lookingland K; Lutzke BS; Mccall RB; Piercey MF; Schreur PJ; Sethy VH; Smith MW; Svensson KA; Tang AH; Vonvoigtlander PF; Tenbrink RE
    J Pharmacol Exp Ther; 1996 Dec; 279(3):1392-403. PubMed ID: 8968364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of [3H]quinpirole binding to D2-like dopamine receptors in rat brain.
    Levant B; Grigoriadis DE; DeSouza EB
    J Pharmacol Exp Ther; 1992 Sep; 262(3):929-35. PubMed ID: 1356154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopamine D4 receptors inhibit depolarization-induced [3H]GABA release in the rat subthalamic nucleus.
    Floran B; Floran L; Erlij D; Aceves J
    Eur J Pharmacol; 2004 Sep; 498(1-3):97-102. PubMed ID: 15363981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacology of a human dopamine D4 receptor expressed in HEK293 cells.
    Lawson CF; Mortimore RA; Schlachter SK; Smith MW
    Methods Find Exp Clin Pharmacol; 1994 Jun; 16(5):303-7. PubMed ID: 7934308
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological characterization of extracellular acidification rate responses in human D2(long), D3 and D4.4 receptors expressed in Chinese hamster ovary cells.
    Coldwell MC; Boyfield I; Brown AM; Stemp G; Middlemiss DN
    Br J Pharmacol; 1999 Jul; 127(5):1135-44. PubMed ID: 10455259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [3H]-quinelorane binds to D2 and D3 dopamine receptors in the rat brain.
    Gackenheimer SL; Schaus JM; Gehlert DR
    J Pharmacol Exp Ther; 1995 Sep; 274(3):1558-65. PubMed ID: 7562534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.